
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Menstruation is a normal part of adolescence, but for girls with excessive bleeding, it can be associated with significant morbidity.






